Visit
VJHemOnc is an official Media Partner for the 1st Texas MPN Workshop which takes place on 27-28 August.
Being held online over two days, the meeting will provide state-of-the-art presentations and interactive discussions for a world-leading myeloproliferative neoplasms (MPNs) faculty.
Texas MPN Workshop 2020
First results of the 2nd H2H of iBTKs: the ALPINE study. With a 15 months follow up.
So different population from ELEVATE RR #iwCLL2021 @PeterHillmen #CLL
⭐@ninashah33 of @UofCalifornia gives us all the latest developments on the use of alloCAR-T therapies ⭐
Watch: 👉http://ow.ly/k1V050G7DAQ👈
@SocietyofHemOnc #SOHO2021 #HemOnc #ImmunoOnc #CART #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
In advance of our 2nd debate at #iwCLL2021 between Peter Dreger and @drjgauthier, which type of cellular therapy do you prefer for your patients with CLL?
Texas MPN Workshop 2020
VJHemOnc is an official Media Partner for the 1st Texas MPN Workshop which takes place on 27-28 August.
Being held online over two days, the meeting will provide state-of-the-art presentations and interactive discussions for a world-leading myeloproliferative neoplasms (MPNs) faculty.
First results of the 2nd H2H of iBTKs: the ALPINE study. With a 15 months follow up.
So different population from ELEVATE RR #iwCLL2021 @PeterHillmen #CLL
⭐@ninashah33 of @UofCalifornia gives us all the latest developments on the use of alloCAR-T therapies ⭐
Watch: 👉http://ow.ly/k1V050G7DAQ👈
@SocietyofHemOnc #SOHO2021 #HemOnc #ImmunoOnc #CART #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM
In advance of our 2nd debate at #iwCLL2021 between Peter Dreger and @drjgauthier, which type of cellular therapy do you prefer for your patients with CLL?
VJHemOnc is intended for Healthcare Professionals onlyBy choosing to continue, you are confirming that you are a healthcare professional
Sign-up for our Newsletter!
Keep up to date with all the latest news with our monthly newsletter
